Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib add-on boosted myeloma response

Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

Key clinical point: The JAK 1/2 inhibitor ruxolitinib, in combination with lenalidomide and methylprednisolone, overcame resistance to lenalidomide in about half of heavily pre-treated patients with relapsed/refractory multiple myeloma in a phase I trial.

Major finding: The overall response rate was 39%, and the clinical benefit rate was 50% (13 of 26 patients).

Study details: A phase 1 study including 28 patients with relapsed/refractory multiple myeloma who had previous treatment with lenalidomide/steroids and a proteasome inhibitor.

Disclosures: Dr. Berenson, the presenting author, had disclosures related to Amgen, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Takeda, and OncoTracker.

Source: Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

Read the article.

Citation:

Berenson JR, et al. J Clin Oncol 36, 2018, suppl. (ASCO 2018, annual meeting of the American Society of Clinical Oncology); abstr 8005.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Multiple Myeloma

Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301

Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123

RNA editing contributes to myeloma pathogenesis, Teoh PJ et al. Blood. 2018;132(12):1304-17

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.